Adaptive Biotechnologies (ADPT) Total Liabilities (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Total Liabilities data on file, last reported at $281.7 million in Q1 2026.

• Quarterly Total Liabilities fell 12.14% year-over-year to $281.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.7 million (down 12.14% YoY) and the FY2025 annual result came in at $287.7 million, down 14.59% from the prior year.
• Total Liabilities fell to $281.7 million in Q1 2026 per ADPT's latest filing, from $287.7 million in the prior quarter.
• The five-year high for Total Liabilities was $396.4 million in Q3 2022, with the low at $281.7 million in Q1 2026.
• Average Total Liabilities over 5 years is $334.2 million, with a median of $336.9 million recorded in 2024.
• Year-over-year, Total Liabilities retreated 15.22% in 2022 and rose 27.84% in 2023.
• Adaptive Biotechnologies' Total Liabilities stood at $392.5 million in 2022, then slipped by 10.1% to $352.9 million in 2023, then declined by 4.52% to $336.9 million in 2024, then decreased by 14.59% to $287.7 million in 2025, then retreated by 2.1% to $281.7 million in 2026.
• Business Quant data shows ADPT's Total Liabilities at $281.7 million in Q1 2026, $287.7 million in Q4 2025, and $286.4 million in Q3 2025.